Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
نویسندگان
چکیده
منابع مشابه
Combination lipid therapy in type 2 diabetes.
To the Editor: In the Action to Control Car diovascular Risk in Diabetes (ACCORD) trial (ClinicalTrials.gov number, NCT00000620) report ed on by Ginsberg et al. (April 29 issue),1 the use of fenofibrate in patients with type 2 diabetes mellitus who were receiving simvastatin and who were at high risk for cardiovascular disease great ly reduced triglyceride levels but hardly increased levels ...
متن کاملOptimizing combination treatment in the management of type 2 diabetes
Obtaining the suggested glycemic control is the most important achievement in order to prevent cardiovascular complications in patients with type 2 diabetes. Monotherapy often fails after a period of treatment, so that multiple drugs are needed to achieve effective glycemic control. A number of oral glucose lowering drugs is now available such as metformin, sulfonylureas, non-sulfonylureas secr...
متن کاملEffects of combination lipid therapy in type 2 diabetes mellitus.
BACKGROUND We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. METHODS We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either ...
متن کاملPractical combination therapy based on pathophysiology of type 2 diabetes
Type 2 diabetes is a complex, chronic, and progressive condition that often necessitates the use of multiple medications to achieve glycemic goals. Clinical guidelines generally recommend intensifying pharmacotherapy if glycemic goals are not achieved after 3 months of treatment. However, for many patients with type 2 diabetes, treatment intensification is delayed or does not occur. Initiating ...
متن کاملPioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
INTRODUCTION Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large cl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Therapy
سال: 2019
ISSN: 0741-238X,1865-8652
DOI: 10.1007/s12325-018-0868-9